More recently, Denosumab, a human monoclonal antibody against RANKL, confirmed its superiority over zoledronid acid giving an overall survival improvement in a population of 811 NSCLC patients with bone metastases[28,29]. Here, TNFSF11 is linked to non-small cell lung carcinoma.